Latest Breaking News On - Bc cancer centre for lymphoid - Page 1 : comparemela.com

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

Fixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lymphoma, according to updated data from the phase 2 GO29781 trial.

British columbiaUnited statesUnited kingdomLaurieh sehnInternational conference on malignant lymphomaBc cancer centre for lymphoidUniversity of british columbiaAmerican society for transplantationInternational conferenceLymphoid cancerAmerican societyCellular therapyAnn arborFollicular lymphomaFixed durationComplete response

Health Canada Authorizes POLIVY® (polatuzumab vedotin for injection) for the First-Line Treatment of Adults With Large B-Cell Lymphoma

In Canada, it is estimated that in 2022, 11,400 Canadians will be diagnosed with non-Hodgkin lymphoma1, of which 30-40% of cases are diffuse large B-cell.

United kingdomAntonella rizzaAmy haddleseyLaurie sehnWorld health organization classification of haematolymphoid tumoursLymphoma society of canadaBc cancer centre for lymphoidLymphoma tumour groupCanadian cancer societyStrategic communicationsUniversity of british columbiaRoche limited canadaDivision of medical oncologyHealth canadaHealth canada approvalRoche canada

Isatuximab Added to RVd Boosts Response in New Myeloma

The addition of the anti-CD38 antibody improved minimal residual disease rates at the end of induction, a marker for better outcomes following autologous stem cell transplant.

United statesBritish columbiaBaden wübergWashington universitySiteman cancer centerLaurie sehnHartmut goldschmidtRavi vijBc cancer centre for lymphoidInternational staging systemDrug administrationUniversity hospital heidelbergWashington university school of medicineAmerican society of hematologyMedscape medicalWashington university school

Remarkable Results With CAR T Cells Could Make Chemo Obsolete

Chemotherapy, the decades-old approach to second-line therapy for relapsed/refractory large B cell lymphomas, may soon be obsolete, investigators say.

United statesBritish columbiaManali kamdarFrederickl lockeLaurie sehnAmerican society of hematologyAmerican society of hematology annual meetingBc cancer centre for lymphoidUniversity of colorado cancer centerMoffitt cancer centerColorado cancer centerLymphoid cancerNew england journalMedscape medical newsAmerican societyHematology annual meeting

Incyte Announces Health Canada Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte Announces Health Canada Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomCatalina lovemanChristine chiouLaurie sehnJenifer antonacciPractice research clinical haematologyXencor incBc cancer centre for lymphoidDrug administrationHead of medical affairs incyte biosciences canadaExchange commissionUniversity of british columbiaHealth canadaIncyte biosciences canadaClinical professor